Navigation Links
FDA Grants QT Ultrasound® Breakthrough Device Designation

Today the Food and Drug Administration (FDA) granted QT Ultrasound LLC’s Breakthrough Device designation request for its QT Scanner 2000 Model A. Unlike traditional breast imaging modalities, the company’s QTscan™ has no radiation, no injections, and no compression, potentially offering new opportunities for earlier and more frequent screening for young women at high risk for breast cancer, who have no available FDA-cleared screening options.

Women at high risk have a 20% lifetime risk of developing breast cancer.* Causes include genetic factors, family history, and exposure to radiation. With one first-degree female relative, such as a mother or sister, diagnosed with breast cancer, a woman’s risk is doubled. Women who carry a mutation in their BRCA 1 or BRCA 2 genes have a 40-85% lifetime risk of developing breast cancer and are more likely to develop breast cancer at a younger age.* While only about 7% of women with breast cancer are diagnosed before the age of 40 years, the most aggressive form of breast cancer and the worst survival rates occur in younger women.* However, routine mammograms are not recommended for women under 40 years old. Quantitative Transmission Ultrasound is an emerging trend in ultrasound technology that can see through dense breasts and uses no radiation, giving it the potential to have significant benefits for younger women at high risk. “Breast cancer screening is important for all women, but women who are at a higher risk of breast cancer may need to be screened earlier and more often than other women. We hope to provide an imaging option that is safe, comfortable, and effective.” Says Dr. John Klock, CEO and Founder of QT Ultrasound.

The proposed indications for use, as designated by the FDA as breakthrough are:
“The QT Ultrasound Breast Scanner is an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast, without emitting ionizing radiation. The device is intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer based upon genetic testing and/or other established criteria, who have not reached the age of mammography screening for their risk level in applicable breast cancer screening guidelines. Diagnostic work-up of findings may follow as clinically appropriate. The QT Scanner is not to be used as a replacement for standard screening mammography.”

The company will be working with the FDA to submit an appropriate pre-market submission. If approved, the device may be legally marketed for use as a breast cancer screening device in younger women at high risk for breast cancer.

About QT Ultrasound
QT Ultrasound® is a privately held company engaged in the research, development, and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images. The company has received FDA clearance for its QTscan™, and the National Institutes of Health (NIH) awarded over $15 million in funding to continue QT Ultrasound research. The company’s clinical trials have been conducted at prestigious institutions in the US and Europe and include ongoing trials at the Marin Breast Health Trial Center in Novato, California. QTscans are now available commercially through the breast imaging centers of QTbreasthealth™.

The QT Ultrasound Breast Scanner is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.

For more information about QT Ultrasound, visit
For more information about the commercially available QTscan, visit
For more information about clinical trials, visit

American Cancer Society, Rethink Breast Cancer, NCBI

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related medicine technology :

1. Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care
2. WellCare Announces $20,000 in Grants to Help Reduce Tobacco Use and Promote Smoke-Free Environments in Kentucky
3. Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Spain
4. FDA Grants Orphan Drug Designation to CSRAs DynPort Vaccine Company for Plague Vaccine
5. Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists
6. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
7. FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
8. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
9. FDA Grants Orphan Drug Designation to Debiopharm International SAs IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
10. Superdisintegrants Market Worth 416.5 Million USD by 2021
11. FDA Grants Second Orphan Designation For VAL-083
Post Your Comments:
(Date:11/13/2018)... ... November 13, 2018 , ... The ... group to head business development and partnerships. Rick has spent much of his ... Management to Service to Sales, Rick brings his extensive background in the industry ...
(Date:11/13/2018)... ... ... The well-respected local dental team of Drs. Steven White and Brad Haines has ... implants in Cornelius, NC. The incentive includes $200 off all dental implant treatments, ... implants are considered to be one of the gold standards in tooth replacement solutions. ...
(Date:11/13/2018)... ... November 13, 2018 , ... Loyale Healthcare today ... will concentrate on larger healthcare enterprises, where Loyale’s Patient Financial Manager™ has proven ... integrated patient experiences. , Mr. Sykes’ distinguished healthcare career includes more than ...
Breaking Medicine Technology:
(Date:11/14/2018)... ... 14, 2018 , ... For what is a first time at the annual ... Disorders, will present an overview of the EFFT model with a focus on supporting ... 2019 event. , Next year’s 33rd iaedp™ Symposium is slated for February 7-10, ...
(Date:11/14/2018)... Texas (PRWEB) , ... November 14, 2018 , ... The ... as the New Year approaches, it’s time to pull out the healthcare plan paperwork ... a self-purchased plan or sponsored by an employer, most people can benefit by taking ...
(Date:11/13/2018)... ... November 14, 2018 , ... REMS: Requirements, Regulation, and ... 2018 — 1:30 p.m. – 3:00 p.m. ET, ... powerful enforcement tool. A constantly evolving enforcement tool. , In September the FDA ...
(Date:11/13/2018)... ... ... A survey by the publishers of ADC Review | Journal of ... U.S. $ 4 billion. Approximately forty-five percent of this market included Antibody-drug Conjugates (ADCs). ... is expected to grow significantly, to U.S. $ 17 billion by 2023. [1][2][3] , ...
(Date:11/13/2018)... ... November 13, 2018 , ... The Centers for Medicare and ... and identified seven high volume current procedural terminology (CPT) codes as potentially misvalued, ... requested the RUC (Relative Value Update Committee) of the American Medical Association re-evaluate ...
Breaking Medicine News(10 mins):